Please assess the completion status of the following clinical trial:

Trial Title: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet all of the following inclusion criteria before enrollment:~* Histologically or cytologically confirmed PTCL (all subtypes) or CTCL (mycosis fungoides/Sezary syndrome) as defined by 2016 World Health Organization (WHO) classification.~For patients with PTCL:~* Patients must have relapsed/refractory disease to one or more systemic therapies.~* Patients with CD30-positive lymphoma must have received, be ineligible for, or intolerant to brentuximab vedotin.~* Patients with limited prior exposure to Bendamustine (less than 2 full cycles or ≤ 480 mg/m2) may be included, based on PI discretion.~* Patients must have measurable disease (e.g., a tumor mass \>1 cm or evidence of bone marrow involvement).~For patients with CTCL, Stage IB-IVB mycosis fungoides or Sezary syndrome are eligible~* Patients must have relapsed/refractory disease to at least one previous systemic therapy. Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a systemic therapy.~* Male and female patients 18 years of age and older~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~* Expected survival greater than 3 months.~* Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.~* Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.~* At least 2 weeks must have elapsed from prior chemotherapy drugs (other than steroids) or radiation~* At least 6 weeks must have elapsed from prior autologous stem cell transplant and 12 weeks must have elapsed from prior allogeneic stem cell transplant.~* Laboratory values ≤2 weeks must be: Adequate hematological function (absolute neutrophil count \[ANC\] ≥1,500/mm3, platelets ≥100,000/mm3). In subjects with known bone marrow involvement, ANC must be ≥ 1000/mm3 and platelets ≥75,000/mm3; Adequate hepatic function (aspartate aminotransferase \[AST/SGOT\] less than or equal to 3x upper normal limit \[UNL\], alanine aminotransferase \[ALT/SGPT\] less than or equal to 3x UNL (≤5x UNL if liver metastases present), bilirubin less than or equal to 1.5x UNL); Adequate renal function (serum creatinine less than or equal to 1.5 mg/dL or 133 µmol/L).~* No evidence of current infection.~* Mentally competent, ability to understand and willingness to sign the informed consent form.~Exclusion Criteria:~* Patients with the following characteristics are excluded:~* Known cerebral metastases, central nervous system (CNS) or epidural tumor.~* History of prior malignancy and considered to be at greater than 30% risk of relapse~* Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs (steroids are allowed)~* Patients with a history of allogeneic transplant must not have ≥ grade 3 graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic immunosuppression.~* Serious medical illness that would potentially increase patients' risk for toxicity.~* Pregnant women, or women of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown).~* Lactating females.~* Fertile men unwilling to practice contraceptive methods during the study period.~* Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.~* Unwilling or unable to follow protocol requirements.~* Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction or symptomatic congestive heart failure.~* Evidence of current infection..~* Patients with known HIV infection, hepatitis B, or hepatitis C with positive viral load.~* Patients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPI-613 in Combination with Bendamustine (Type: EXPERIMENTAL): CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).